Solid cancers after allogeneic hematopoietic cell transplantation

  • J. Douglas Rizzo
    Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee;
  • Rochelle E. Curtis
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD;
  • Gérard Socié
    Hôpital Saint Louis, Paris, France;
  • Kathleen A. Sobocinski
    Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee;
  • Ethel Gilbert
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD;
  • Ola Landgren
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD;
  • Lois B. Travis
    James P. Willmot Cancer Center, Rochester, NY;
  • William D. Travis
    Memorial Sloan-Kettering Cancer Center, New York, NY;
  • Mary E. D. Flowers
    Fred Hutchinson Cancer Research Center, Seattle, WA; and
  • Debra L. Friedman
    Fred Hutchinson Cancer Research Center, Seattle, WA; and
  • Mary M. Horowitz
    Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee;
  • John R. Wingard
    Shands Hospital, Gainesville, FL
  • H. Joachim Deeg
    Fred Hutchinson Cancer Research Center, Seattle, WA; and

抄録

<jats:title>Abstract</jats:title> <jats:p>Transplant recipients have been reported to have an increased risk of solid cancers but most studies are small and have limited ability to evaluate the interaction of host, disease, and treatment-related factors. In the largest study to date to evaluate risk factors for solid cancers, we studied a multi-institutional cohort of 28 874 allogeneic transplant recipients with 189 solid malignancies. Overall, patients developed new solid cancers at twice the rate expected based on general population rates (observed-to-expected ratio 2.1; 95% confidence interval 1.8-2.5), with the risk increasing over time (P trend < .001); the risk reached 3-fold among patients followed for 15 years or more after transplantation. New findings showed that the risk of developing a non–squamous cell carcinoma (non-SCC) following conditioning radiation was highly dependent on age at exposure. Among patients irradiated at ages under 30 years, the relative risk of non-SCC was 9 times that of nonirradiated patients, while the comparable risk for older patients was 1.1 (P interaction < .01). Chronic graft-versus-host disease and male sex were the main determinants for risk of SCC. These data indicate that allogeneic transplant survivors, particularly those irradiated at young ages, face increased risks of solid cancers, supporting strategies to promote lifelong surveillance among these patients.</jats:p>

収録刊行物

  • Blood

    Blood 113 (5), 1175-1183, 2009-01-29

    American Society of Hematology

被引用文献 (22)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ